Carbidopa and Levodopa Tablets — Class II drug recall D-0432-2023
Terminated recall by The Harvard Drug Group, reported 2023-03-08, distributed nationwide. Packaging defect: observed packaging defect, blister packaging inadequately sealed.
| Recall number | D-0432-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | The Harvard Drug Group, La Vergne, TN, United States |
| Recall initiated | 2023-02-23 |
| Classified | 2023-03-02 |
| Reported by FDA | 2023-03-08 |
| Terminated | 2024-04-30 |
| Distributed | Nationwide (US) |
| Quantity | 17,586 cartons |
| Reason classes | packaging |
| UPC / GTIN / UDI-DI | 00309047257614 |
| NDC | 00904-7257-61 |
| Lot numbers | M04145 |
| Expiration dates | 2024-01 |
Product
Carbidopa and Levodopa Tablets, USP 25 mg/100 mg, 10x10 Unit Dose carton, Rx Only, Manufactured in Czech Republic by: Teva Czech Industries, s.r.o. Opava-Komarov, Czech Republic, Manufactured for: Teva Pharmaceuticals USA, Inc. Parsippany, NJ 07054, Packaged and Distributed by: Major Pharmaceuticals Indianapolis, IN 46268 USA. NDC 0904-7257-61, UPC 3 09047 25761 4
Reason for recall
Packaging defect: observed packaging defect, blister packaging inadequately sealed.
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0432-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.